Quinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Patients: Effect of Augmented Gram-Positive Activity on Infectious Morbidity

Annals of Internal Medicine

Volumn 125, Issue 3, 1996, Pages 183-190

  Bow, Eric J ^a   Mandell, Lionel A ^b   Louie, Thomas J ^c   Feld, Ronald ^d   Palmer, Michael ^e   Zee, Benny ^e   Pater, Joseph ^e  

^a HEALTH SCIENCES CENTRE   (Canada)

^b HENDERSON GENERAL HOSPITAL   (Canada)

^c Princess Margaret Hospital ^*  (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; NORFLOXACIN; OFLOXACIN; RIFAMPICIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL COUNT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BACTEREMIA; COLONY COUNT, MICROBIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; NORFLOXACIN; OFLOXACIN; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 0030213709     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-3-199608010-00004     Document Type: Article

References (49)

1. Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987;106:1-7.
2. Winston DJ, Ho WG, Champlin RE, Karp J, Bartlett J, Finley RS, et al. Norfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med. 1987;82:40-6.
3. Bow EJ, Ronald AR. Antibacterial chemoprophylaxis in neutropenic patients - where do we go from here? [Editorial] Clin Infect Dis. 1993;17:333-7.
4. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987;106:7-11.
5. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med. 1988;84:847-54.
6. Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. Eur J Cancer. 1992;28A:873-8.
7. Bow EJ, Loewen R, Vaughan D. Reduced requirement for gram-negative antibiotic therapy in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis. 1996; 20:907-12.
8. Karp JE, Dick JD, Angelopulos C, Charache P, Green L, Burke PJ, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med. 1986;81:237-42.
9. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis. 1991;163:951-8.
10. Fuchs PC. In vitro antimicrobial activity and susceptibility testing of ofloxacin. Current status. Am J Med. 1989;87(Suppl 6C):10S-35.
11. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1990;88:36-42.
12. Liang RH, Yung RW, Chan TK, Chau PY, Lam WK, So SY, et al. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990;34:215-8.
13. Arning M, Wolf HH, Aul C, Heyll A, Scharf RE, Schelder W. Infection prophylaxis in neutropenic patients with acute leukemia - a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin. J Antimicrob Chemother. 1990;26(Suppl D):137-42.
14. Sawada H, Tashima M, Okina M. Use of ofloxacin in prevention and treatment of secondary infections in hematological malignancies. Chemotherapy. 1991;37(Suppl 1):25-32.
15. Gluckman E, Roudet C, Hirsch I, Devergie A, Bourdeau H, Arlet C, et al. Prophylaxis of bacterial infections after bone marrow transplantation. A randomized prospective study comparing oral broad-spectrum nonabsorbable antibiotics (vancomycin-tobramycin-colistin) to absorbable antibiotics (ofloxacin-amoxicillin). Chemotherapy. 1991;37(Suppl 1):33-8.
16. Pizzo PA, Robichaud KJ, Edwards BK, Schumaker C, Kramer BS, Johnson A. Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. J Pediatr. 1983;102:125-33.
17. Kramer BS, Carr DJ, Rand KH, Pizzo PA, Johnson A, Robichaud KJ, et al. Prophylaxis of fever and infection in adult cancer patients. A placebo-controlled triai of oral trimethoprim-sulfamethoxazole plus erythromycin. Cancer. 1984;53:329-35.
18. Warren RE, Wimperis JZ, Baglin TP, Constantine CE, Marcus R. Prevention of infection by ciprofloxacin in neutropenia. J Antimicrob Chemother. 1990;26(Suppl F):109-23.
19. Rozenberg-Arska M, Dekker A, Verdonck L, Verhoef J. Prevention of bacteremia caused by α-hemolytic streptococci by roxithromydn (RU-28 965) in granulocytopenic patients receiving ciprofloxacin. Infection. 1989;17:240-4.
20. Guiot HF, van der Meer JW, van den Broek PJ, Willemze R, van Furth R. Prevention of viridans group streptococcal septicemia in oncohematologic patients: a controlled comparative study of the effect of penicillin G and cotrimoxazole. Ann Hematol. 1992;64:260-5.
21. Bochud PY, Eggiman P, Calandra T, van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25-31.
22. Louie TJ, Bow EJ, Krulicki W, Gray G. Efficacy of quinolones for the prevention of bacteremia in neutropenic rats. Rev Infect Dis. 1989;11 (Suppl 5):1242-3.
23. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990;161:381-96.
24. Bow EJ, Louie TJ, Riben PD, McNaughton RD, Harding GK, Ronald AR. Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients. Am J Med. 1984;76:223-33.
25. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis. 1990;161:397-401.
26. Kaplan EH, Meier B. Non-parametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-81.
27. Cox DR. Regression models and life-tables Journal of the Royal Statistical Society. 1972;34:187-220.
28. 14C by Myco bacterium phlei. Am Rev Respir Dis. 1973;107:1006-12.
29. Thomsberry C, Hill BC, Swenson JM, McDougal LK. Rifampin: spectrum of antibacterial activity. Rev Infect Dis. 1983;5(Suppl 3):S412-7.
30. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxadn. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Ann Intern Med. 1991;115:7-12.
31. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med. 1994;97:256-64.
32. Kern W, Kurrie E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection. 1990;18:138-45.
33. Attal M, Schlaifer D, Ruble H, Huguet F, Charlet JP, Bloom E, et al. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomydn: a prospective, randomized trial. J Clin Oncol. 1991;9:865-70.
34. Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J, et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol. 1994;12:1005-11.
35. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol. 1990;8:1591-7.
36. Shay DK, Maloney SA, Montecalvo M, Bannerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995;172:993-1000.
37. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995;21:361-9.
38. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75:27-32.
39. Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematologic malignancies. J Infect Dis. 1985;152: 99-103.
40. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991;51:630-6.
41. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995;13:239-50.
42. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681-7.
43. Carratala J, Fernandez-Sevllla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20:557-60.
44. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995;39:520-4.
45. Ball P. Editorial response: is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis? Clin Infect Dis. 1995;20:561-3.
46. Rosenberg-Arska M, Dekker AW, Verhoef J. Colistin and trimethoprim-sulfamethoxazole for the prevention of infection in patients with acute non-lymphocytic leukemia. Decrease in the emergence of resistant bacteria. Infection. 1983;11:167-9.
47. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-7.
48. Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobulin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest. 1993;23:540-5.
49. de Marie S, van den Broek PJ, Willemze R, van Furth R. Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis. 1993;12:897-906.